Long-Term Liabilities: Prime Medicine Corp (PRME)

Graphic logo of Prime Medicine Inc (PRME)

The GURU.Markets price evolution chart for Prime Medicine, Inc. (PRME) shows debt at the level of 0.11. The business relies on a unique precision gene editing method, creating a powerful patent barrier. An extensive network of laboratories with secured logistics guarantees profit stability. However, Prime Medicine, Inc. (PRME) faces ethical challenges and lengthy testing cycles, which increase its dependence on intellectual property rights.

PRME - Prime Medicine Company Long-Term Debts over the range 04/28/2023 - 10/31/2026

Prime Medicine Corp (PRME) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price primemedicine.com|PRME - Price Target Chart
- company stock exchange capitalization indicators:
Market Valuation Prime Medicine|PRME - Total Company Value
- book capitalization indicators:
Accounting Value of a Share Prime Medicine|PRME - Book Capitalization|Market Capitalization to Book Value primemedicine.com|PRME - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Equity Ratio Prime Medicine, Inc.|PRME - Long-Term Debt to Capital|Current Liabilities to Capital Prime Medicine Bio|PRME - Company Total Debt|Debt to Net Assets Ratio Prime Medicine|PRME - Company Long-Term Debt|Company Current Liabilities Prime Medicine|Immediate Liquidity primemedicine.com
- earnings and market ratios statistics:
PRME - Net Profit
Fundamental company valuation:primemedicine.com
Mass-produced product of Prime Medicine

Driven by its unique "prime editing" DNA technology, Prime Medicine, Inc. (PRME) possesses exceptional pricing power within a market characterized by inelastic demand. By analyzing the company's long-term debt history, an investor assesses total liabilities with maturities exceeding one year, enabling a rapid diagnosis of risks regarding balance sheet deterioration and a determination of the business's actual solvency in the context of its fundamental value.

Competitors of Prime Medicine, Inc. (PRME)

Company Long-Term Debts Tempus Labs TEM|QGEN - Company Long-Term Debt|Long-Term Liabilities IONS|Repligen Corp. (RGEN) - Company Long-Term Debt|Avidity Corp - Company Long-Term Loans and Borrowings|CRSP (CRISPR Therapeutics AG) - Company Long-Term Debts|genedx.com (WGS) - Long-Term Debt Volume|Company Long-Term Debt Ultragenyx (RARE)|Company Long-Term Liabilities Beam Therapeutics Inc BEAM|Company Long-Term Debts SRPT (Sarepta Therapeutics Inc)|Twist Bioscience Corp (TWST) - Long-Term Debt|TXG: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings NTLA (intelliatx.com)|Stoke Therapeutics, Inc. (STOK) - Company Long-Term Debt|Company Long-Term Liabilities BioLife Solutions Inc|WVE (Wave Life Sciences Corp) - Company Long-Term Debts|Long-Term Debt Maze Therapeutics Corp MAZE|Company Long-Term Debts SION|tayshagtx.com - Company Long-Term Indebtedness|Company Long-Term Debts QURE (uniQure)|Long-Term Debt Volume MeiraGTx Holdings (MGTX)|Regenxbio - Company Long-Term Debts|Solid Corp (SLDB) - Company Long-Term Liabilities|OCGN: Company Long-Term Debts|PACB - Long-Term Debt Volume|Company Long-Term Debt Benitec Biopharma|Company Long-Term Indebtedness DSGN (Design Therapeutics Inc)|Company Long-Term Debts RCKT|FDMT - Long-Term Debt|Lexeo Therapeutics, Inc. - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings KRRO|Editas Medicine - Company Long-Term Debts|Long-Term Debt Volume Silence Therapeutics PLC SLN|proqr.com (PRQR) - Company Long-Term Debt|Company Long-Term Indebtedness CDXS|SGMO (Sangamo Therapeutics) - Company Long-Term Debts|Company Long-Term Liabilities Nautilus Biotechnology Inc (NAUT)|Company Long-Term Liabilities MGX (Metagenomi)|Long-Term Debt Volume Precision BioSciences Inc.|Company Long-Term Debt Generation Bio GBIO|BOLD (Boundless Bio Inc) - Long-Term Liabilities|XCUR - Company Long-Term Debt|Company Long-Term Loans and Borrowings IMNN (Imunon, Inc.)|phiopharma.com (PHIO) - Company Long-Term Debt|Company Long-Term Liabilities Mustang Bio|RNAZ (TransCode Therapeutics Inc.) - Company Long-Term Debts|Long-Term Debt Bionano BNGO|Company Long-Term Debts APDN|bluebirdbio.com - Company Long-Term Indebtedness|Company Long-Term Debt ImmunoPrecise Antibodies Ltd. IPA|OMGA: Company Long-Term Indebtedness|Singular Genomics Systems Inc - Company Long-Term Debts|RGLS - Company Long-Term Debts|Syros Pharmaceuticals (SYRS) - Company Long-Term Debt|Long-Term Liabilities TBIO (telesisbio.com)|Company Long-Term Debt TRACON Pharmaceuticals, Inc.|UBX: Company Long-Term Loans and Borrowings